Interim report
Page 1
2025/26 Interim financial results, 9M 2025/26 1 October 2025 - 30 June 2026 Coloplast delivered Q3 organic growth of 6% and 5% EBIT growth1 in constant currencies. Strong quarter in both Chronic Care ex. China and Interventional Urology; continued reimbursement-related challenges in Biologics. Reported revenue in DKK also grew 6%, as currencies had a net neutral impact. Return on invested capital after tax before special items was 15%. • Organic growth rates by business area: Ostomy Care 5%, Continence Care 8%, Voice & Respiratory Care 6%, Wound & Tissue Repair 3%, and Interventional Urology 7%. • Strong quarter in Ostomy Care ex. China, with strong double-digit growth in the US and solid performance in Europe and Emerging markets ex. China. • Strong quarter in Continence Care, with double-digit growth in the US and solid growth in Europe, driven by Luja. • Solid quarter in Voice & Respiratory Care, with strong growth in Laryngectomy and softer quarter in Tracheostomy. • Challenging quarter in Biologics with 6% sales decline and -5% EBIT margin before PPA amortisation, due to the reimbursement change. • Advanced Wound Dressings grew 4%: good momentum in the US and positive impact from phasing in Germany and the Middle East, partly offset by the China product return. • Continued strong momentum in Interventional Urology, driven by the US Men’s Health business. • EBIT1,2 was DKK 1,929 million. EBIT1,2 in constant currencies increased 5% compared to last year, while reported EBIT1,2 increased 1% from last year. The EBIT margin1,2 was 26%, against 28% last year, and includes around 110 basis points negative impact from currencies and around 60 basis points negative impact from Kerecis. 9M 2025/26 organic growth of 6% and 5% EBIT growth1 in constant currencies. Reported revenue in DKK grew 3%, reflecting 3%-points negative impact from currencies. • Organic growth rates by business area: Ostomy Care 5%, Continence Care 7%, Voice & Respiratory Care 7%, Wound & Tissue Repair 2%, and Interventional Urology 8%. • EBIT1,2 was DKK 5,599 million. EBIT1,2 in constant currencies increased 5% compared to last year, while reported EBIT1,2 decreased 2% from last year. The EBIT margin1,2 was 26%, against 27% last year, reflecting around 90 basis points negative impact from currencies and around 50 basis points negative impact from Kerecis. • Net profit before special items was DKK 4,289 million, or a DKK 510 million increase from last year (adjusted for the non-recurring tax impact last year), positively impacted by lower net financial items due to gains on exchange rate adjustments, as expected. Adjusted diluted EPS before special items increased by 14%. • The free cash flow-to-sales ratio was 20% vs. 16% last year3, reflecting favourable development in working capital and lower net financial items, partly offset by higher capital expenditures. • Return on invested capital after tax before special items was 15%, on par with last year adjusted4. Unchanged FY 2025/26 guidance: Organic revenue growth expected at 5-6%, EBIT growth in constant currencies at around 5%5. Return on invested capital after tax before special items expected around 15%. • For organic revenue growth we expect continued good momentum in Chronic Care ex. China and high single-digit growth in Interventional Urology. • Kerecis is expected to deliver around 0% organic growth and around 0% EBIT margin. • Reported revenue growth in DKK is expected at around 3%, with 2-3%-points negative impact from currencies. • Capex-to-sales ratio expected around 5%. The effective tax rate is expected around 22%. • Special items is expected around DKK 3.1 billion, reflecting the DKK 3 billion Kerecis impairment loss. ”We deliver a strong Q3 result with 6% organic growth and 5% EBIT growth, which means that we continue to help more and more people with intimate healthcare needs live better lives. My first 100 days have reinforced my conviction that Coloplast is a fundamentally strong company, operating in attractive markets, where we hold leadership positions and see significant growth opportunities. What stands out to me is the strength of our Chronic Care business, the significant untapped potential in the US, and the quality of our people. Today, I am sharing the priorities that I believe will be most important to driving long-term value creation” says Gavin Wood, President & CEO. Announcement no. 07/2026 | 18 August 2026 Conference call Coloplast will host a conference call on Tuesday, 18 August 2026 at 11.00 am CEST. The call is expected to last about one hour. To actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2025/26 Earnings release conference call 1. Before special items of DKK -18 million in Q3 2025/26 and DKK -3,078 million in 9M 2025/26. 2. Before special items of DKK -83 million in Q3 2024/25 and DKK -241 million in 9M 2024/25. 3. Excluding impact from the Uromedica acquisition this year and the Skin Care divestment last year. 4. Last year adjusted for the impact from the Kerecis IP transfer. 5. Before special items expenses of around DKK 3.1 billion in FY 2025/26.
Page 2
Financial highlights and key ratios 1 October 2025 - 30 June 2026, unaudited Consolidated 2025/26 2024/25 2025/26 2024/25 9 mths 9 mths Change Q3 Q3 Change Income statement, DKK million Revenue 21,482 20,914 3 % 7,355 6,958 6 % Research and development costs -782 -697 12 % -281 -239 17 % Operating profit before interest, tax, depr. and amort. (EBITDA) before special items 6,656 6,733 -1 % 2,291 2,258 1 % Operating profit before interest, taxes and amortization (EBITA) before special items 5,978 6,087 -2 % 2,057 2,040 1 % Operating profit (EBIT) before special items 5,599 5,718 -2 % 1,929 1,915 1 % Special items, net -3,078 -241 N/A -18 -83 -78 % Operating profit (EBIT) 2,521 5,477 -54 % 1,911 1,832 4 % Net financial income and expenses -100 -875 -89 % -37 -490 -92 % Profit before tax 2,421 4,602 -47 % 1,874 1,342 40 % Net profit for the period 1,888 2,761 -32 % 1,462 805 82 % Revenue growth, % Period growth in revenue, % 3 4 6 1 Growth break down: Organic growth, % 6 7 6 7 Currency effect, % -3 -2 0 -5 Acquired operations, % 0 – 0 – Divested operations, % 0 -1 0 -1 Balance sheet, DKK million Total assets 46,938 47,880 -2 % 46,938 47,880 -2 % Capital invested 37,308 40,891 -9 % 37,308 40,891 -9 % Net interest-bearing debt (NIBD) 22,986 23,490 -2 % 22,986 23,490 -2 % Equity end of period 13,367 16,448 -19 % 13,367 16,448 -19 % Cash flow and investments, DKK million Cash flows from operating activities 5,409 4,380 23 % 1,711 1,631 5 % Cash flows from investing activities -1,316 -861 53 % -292 -419 -30 % Investments in property, plant and equipment -1,036 -938 10 % -259 -380 -32 % Free cash flow 4,093 3,519 16 % 1,418 1,212 17 % Cash flows from financing activities -4,256 -3,543 20 % -1,680 -1,183 42 % Key ratios Average number of employees, FTEs 17,213 16,814 17,390 16,916 Operating margin (EBIT margin) before special items, % 26 27 26 28 Operating margin (EBIT margin), % 12 26 26 26 Operating margin before interest, tax, depr. and amort., (EBITDA margin), % 31 31 31 31 Gearing ratio, NIBD/EBITDA before special items 2.6 2.6 Return on average invested capital before tax (ROIC), %1⁾ 19 19 20 19 Return on average invested capital after tax (ROIC), %1⁾ 15 11 15 11 Return on equity, % 18 22 45 19 Equity ratio, % 28 34 28 34 Net asset value per outstanding share, DKK 59 73 -19 % 59 73 -19 % Share data Share price, DKK 372 602 -38 % 372 602 -38 % Share price/net asset value per share 6.3 8.2 -24 % 6.3 8.2 -24 % Average number of outstanding shares, millions 225.2 225.4 0 % 225.2 225.4 0 % PE, price/earnings ratio 33.3 36.8 -10 % 14.3 42.1 -66 % Earnings per share (EPS), diluted 8.38 12.25 -32 % 6.49 3.57 82 % Earnings per share (EPS) before special items, diluted 19.03 13.09 45 % 6.55 3.86 70 % Free cash flow per share 18.2 15.6 16 % 6.3 5.4 17 % Announcement no. 07/2026 | 18 August 2026 2 ¹ ⁾ B e f o r e s p e c i a l i t e m s . A f t e r s p e c i a l i t e m s , R O I C b e f o r e t a x w a s 9% (2024/25: 18%), and ROIC after tax was 7% (2024/25: 11%).
Page 3
Sales performance Organic growth in the first nine months of 2025/26 was 6%. Reported revenue in DKK grew 3% to DKK 21,482 million. Exchange rate developments decreased revenue by 3%, mainly related to the depreciation of the USD, GBP, and a basket of Emerging markets currencies against the DKK. The skin care divestment (two months impact) and the Uromedica acquisition (five months impact) had a broadly neutral impact on the reported revenue. Organic growth in Q3 was 6%. Reported revenue in DKK also grew 6% to DKK 7,355 million, as exchange rate developments had a net neutral impact on reported revenue and the Uromedica acquisition had a small positive impact (three months impact). Sales performance by business areas* DKK million Growth composition (9 mths) 2025/26 2024/25 Organic Inorganic Exchange Reported (9 mths) (9 mths) growth rates growth Chronic Care Ostomy Care 7,599 7,415 5 % – -3 % 2 % Continence Care 6,989 6,672 7 % – -3 % 5 % Voice & Respiratory Care 1,788 1,706 7 % – -2 % 5 % Acute Care Wound & Tissue Repair 2,894 3,004 2 % -2 % -3 % -4 % Interventional Urology 2,212 2,117 8 % 1 % -4 % 4 % Revenue 21,482 20,914 6 % 0 % -3 % 3 % DKK million Growth composition (Q3) 2025/26 2024/25 Organic Inorganic Exchange Reported (Q3) (Q3) growth rates growth Chronic Care Ostomy Care 2,589 2,477 5 % – 0 % 4 % Continence Care 2,401 2,233 8 % – 0 % 8 % Voice & Respiratory Care 607 580 6 % – -1 % 5 % Acute Care Wound & Tissue Repair 999 969 3 % – 0 % 3 % Interventional Urology 759 699 7 % 3 % -1 % 8 % Revenue 7,355 6,958 6 % 0 % 0 % 6 % Sales performance by region* DKK million Growth composition (9 mths) 2025/26 2024/25 Organic Inorganic Exchange Reported (9 mths) (9 mths) growth rates growth European markets 12,119 11,535 6 % – -1 % 5 % Other developed markets 5,868 5,912 7 % -1 % -7 % -1 % Emerging markets 3,495 3,467 3 % – -2 % 1 % Revenue 21,482 20,914 6 % 0 % -3 % 3 % DKK million Growth composition (Q3) 2025/26 2024/25 Organic Inorganic Exchange Reported (Q3) (Q3) growth rates growth European markets 4,146 3,920 6 % – 0 % 6 % Other developed markets 2,034 1,901 9 % 1 % -3 % 7 % Emerging markets 1,175 1,137 0 % – 3 % 3 % Revenue 7,355 6,958 6 % 0 % 0 % 6 % Announcement no. 07/2026 | 18 August 2026 3 * The sum of organic growth, divested operations and exchange rates might not match total reported growth due to rounding of numbers.
Page 4
Ostomy Care Ostomy Care generated 5% organic sales growth for the first nine months of 2025/26, with reported revenue in DKK growing by 2% to DKK 7,599 million. Across Europe, US and Emerging markets ex. China, Ostomy Care continued the strong performance and delivered 6% organic growth. Growth in Europe was driven by the UK, Germany and Italy. The US posted strong growth, reflecting a continuation of the positive momentum, while growth in Emerging markets was driven by LATAM. A new sales channel strategy in China led to a significant inventory reduction in Q3, improving China channel economics, but resulting in a temporary negative impact on the growth momentum. From a product perspective, the SenSura Mio portfolio was the main contributor to growth, with good performance across the product range. Within the SenSura Mio portfolio, Convex was the main growth contributor driven by Europe (led by the UK, Germany and Italy) and the US. The SenSura and Assura/Alterna portfolios continued to contribute to growth in Emerging markets ex. China. The Brava range of supporting products delivered strong, broad-based growth, including strong contribution from the US. Our latest innovation continues to perform strongly. The SenSura Mio black bags launch remains significantly ahead of forecast and the new 2-piece click coupling is lifting momentum in the 2- piece click business. We continue to strengthen the portfolio with further variants expected to launch in H1 2026/27. Q3 organic growth was 5%, and reported revenue in DKK increased by 4% to DKK 2,589 million. Ostomy Care excluding China delivered a strong quarter, with organic growth of 7% in Q3. Growth was broad-based across regions ex. China. In Europe, the UK, Italy, and Germany were the main growth contributors. In the US, growth was strong double-digit, reflecting a continuation of the strong underlying momentum from H1. Emerging markets ex. China also delivered strong growth, driven by LATAM. In China, sales declined significantly due to the aforementioned inventory reduction. The underlying performance in China continued to be impacted by the continued weak consumer sentiment and competitive pressures from domestic players in the community channel. The SenSura Mio portfolio was the main contributor to growth in Q3, followed by the Brava range of supporting products. At the product level, SenSura Mio Convex was the main growth contributor, driven by the US and Europe, especially the UK, Italy, and Germany. The SenSura and Assura/Alterna portfolios also contributed to growth in Emerging markets ex. China. Revenue growth in the Brava range of supporting products was broad-based across regions, with particularly strong contribution from the US. Announcement no. 07/2026 | 18 August 2026 4 2.6 billion Reported revenue in DKK for Q3 2025/26 5% 5% 9M 2025/26 Q3 2025/26 Organic growth 5% 2% Organic growth Exchange rates Reported growth Reported growth 2% 4% 9M 2025/26 Q3 2025/26 9M Growth compo- sition (9 mths)-3% Chronic Care
Page 5
Continence Care Continence Care generated 7% organic sales growth for the first nine months of 2025/26, with reported revenue in DKK growing by 5% to DKK 6,989 million. In Intermittent catheters, the largest business in Continence Care, Luja was the main growth contributor, driven by both the male and female catheter in Europe (most notably France, the UK and Germany) and the US. The product continues to be very well-received by users and healthcare professionals. Growth in the SpeediCath portfolio was driven by standard and flexible catheters, in particularly the US and LATAM. Within the smaller business Bowel Care and Collecting Devices, Bowel Care made a strong contribution to growth, driven by the Peristeen portfolio in Europe, while sales of Collecting Devices saw a slight decline in growth in the first nine months. From a geographical perspective, growth was driven by Europe, with solid contribution from the UK, France, and Germany, as well as the US. Growth in Emerging markets was negatively impacted by order phasing. Markets with recent reimbursement openings, such as Australia and Poland, continued to perform well and posted double-digit growth. Q3 organic growth was 8% and reported revenue in DKK increased by 8% to DKK 2,401 million. The Luja portfolio was the main growth contributor in the quarter, driven by solid contribution from Europe, especially the UK and France, as well as the US. Both the male and female catheter continued to perform well and made a solid contribution to growth. Since launch, Luja male has been a key contributor to sustained high single-digit growth in the male catheter business, while Luja female has accelerated growth in the female business to high single-digit, from mid-single digit pre-launch. The SpeediCath portfolio also contributed to growth, driven by the standard and flexible catheters in primarily the US and LATAM. Bowel Care continued its good momentum with strong double-digit growth in the quarter, driven by the Peristeen portfolio in Europe, while Collecting Devices delivered negative growth. From a geographical perspective, growth was driven by the US and Europe, led by the UK, France, and Germany. The US posted strong double-digit growth, with strong contribution from Luja and positive impact from order phasing between Q3 and Q4. Growth in Emerging markets was negatively impacted by order phasing between Q3 and Q4. Announcement no. 07/2026 | 18 August 2026 5 2.4 billion Reported revenue in DKK for Q3 2025/26 7% 8% 9M 2025/26 Q3 2025/26 Organic growth 7% 5% Organic growth Exchange rates Reported growth Reported growth 5% 8% 9M 2025/26 Q3 2025/26 9M Growth compo- sition (9 mths) -3% Chronic Care
Page 6
Voice & Respiratory Care Voice & Respiratory Care generated 7% organic sales growth for the first nine months of 2025/26, with reported revenue in DKK growing by 5% to DKK 1,788 million. Laryngectomy, the largest business in Voice & Respiratory Care, delivered high single-digit growth in the first nine months of 2025/26. Growth was driven by an increase in the number of patients served in existing and new markets and an increase in patient value driven by the Provox Life portfolio, Voice & Respiratory Care’s product line, which allows for a personalised regime. Tracheostomy, the smaller business in Voice & Respiratory Care, delivered mid single-digit growth. From a geographical perspective, growth was broad-based, driven by Europe and the US. Markets with recent reimbursement openings, such as Poland, also made a solid contribution to growth and grew double-digit. Organic growth in Q3 was 6% and reported revenue in DKK increased by 5% to DKK 607 million. Growth in Laryngectomy was high single- digit and continued to be driven by growth in patients served in existing and new markets, as well as an increase in patient value driven by the Provox Life portfolio. Tracheostomy had a softer quarter with low single-digit growth, partly due to order phasing in distributor markets, with orders now expected to shift into Q4. From a geographical perspective, all regions contributed to growth, driven by Europe and the US. Emerging markets continued to be the fastest growing region. Announcement no. 07/2026 | 18 August 2026 6 0.6 billion Reported revenue in DKK for Q3 2025/26 7% 6% 9M 2025/26 Q3 2025/26 Organic growth 7% 5% Organic growth Exchange rates Reported growth Reported growth 5% 5% 9M 2025/26 Q3 2025/26 9M Growth compo- sition (9 mths) -2% Chronic Care
Page 7
Wound & Tissue Repair Wound & Tissue Repair generated 2% organic sales growth for the first nine months of 2025/26. Reported revenue was DKK 2,894 million, a 4% decrease from last year, with 2%-points negative impact from the Skin Care divestment (two months impact). In Advanced Wound Dressings, the largest business in Wound & Tissue Repair, growth was flat at 0% for the first nine months of 2025/26. Strong growth in the US and positive impact from tender phasing in the Middle East was offset by the product return in China, initiated in Q3 last year. From a product perspective, Biatain® Superabsorber was the main growth contributor. Revenue from Biologics, the second largest business, amounted to DKK 865 million in the first nine months of 2025/26 with organic growth of 1%, impacted by the significant sales disruption from the Medicare reimbursement change in the out-patient setting. From a product perspective, SurgiClose® was the main growth contributor. The contract manufacturing business, the smallest business, posted double- digit growth, positively impacted by phasing between Q3 and Q4. Wound & Tissue Repair posted 3% organic growth in Q3, while reported revenue in DKK increased 3% to DKK 999 million. In Advanced Wound Dressings, sales increased 4% in Q3, driven by strong momentum in the US and phasing in Germany and the Middle East, partly offset by China. China detracted from growth due to the aforementioned product return. Q3 revenue from Biologics amounted to DKK 274 million. Organic growth declined 6%, reflecting negative impact from the aforementioned reimbursement change. In July, the Centers for Medicare & Medicaid Services (CMS) published a proposed rule in which the fixed reimbursement rate for skin substitutes in the Medicare out-patient setting is maintained at USD 127/cm2 for 20271. The proposed rule is expected to have neutral impact on our Biologics business. From a product perspective, Biatain® Superabsorber in Advanced Wound Dressings and SurgiClose® in Biologics were the main growth contributors. Announcement no. 07/2026 | 18 August 2026 7 1.0 billion Reported revenue in DKK for Q3 2025/26 2% 3% 9M 2025/26 Q3 2025/26 Organic growth Reported growth -4% 3% 9M 2025/26 Q3 2025/26 -2% 2% Organic growth Divested operations Exchange rates Reported growth 9M Growth compo- sition (9 mths) -3% -2% -4% Acute Care 1 Department of Health and Human Services, Centers for Medicare & Medicaid Services, 42 CFR Parts 413, 416, 419, 427, and 488. [CMS-1850-P]. RIN 0938-AV83. -3%
Page 8
Interventional Urology Interventional Urology generated 8% organic sales growth for the first nine months of 2025/26, with reported revenue in DKK growing by 4% to DKK 2,212 million. The Men’s Health business grew double- digit and was the main growth contributor in the first nine months of 2025/26, driven by the US. Our flagship product within Men’s Health, the Titan Inflatable Penile Prosthesis (IPP), continued to perform well, with the patient funnel positively impacted by our patient support programme targeted at prospective patients. In Kidney & Bladder Health, growth reflected an easier baseline from the voluntary product recall initiated in Q1 last year, as well as contribution from the Coloplast TFL Drive Thulium Fiber Laser. The Women’s Health business delivered a modest contribution to growth. From a geographical perspective, the US was the main growth contributor, while Europe also contributed nicely to growth. Q3 organic growth was 7% and reported revenue in DKK increased by 8% to DKK 759 million. Growth in Q3 was mainly driven by the Men’s Health business in the US, which delivered double-digit growth, driven by the Titan IPP. In June 2026, Coloplast received FDA approval for Titan Prime IPP in the US, Coloplast’s next-generation IPP. The product is expected to launch within the coming months, with the innovation expected to support Men’s Health growth in the Impact4 period1. Performance in Uromedica (the company acquired in February 2026 and the latest addition to the Men’s Health portfolio) was likewise strong, with revenues exceeding expectations. The acquisition continues to be well received by our existing Men’s Health customers, further strengthening our portfolio with a highly complementary product offering. In Kidney & Bladder Health, growth was driven mainly by an easier baseline from the voluntary product recall last year. From a geographical perspective, the US continued to be the main growth contributor, followed by Europe. Intibia, Coloplast's implantable tibial nerve stimulatory system for urge urinary incontinence2, demonstrated significant quality-of-life benefits versus sham treatment, sustained through 12 months3. Following PMA submission in Q1 2025/26, US launch is now expected at the beginning of 2027/28 due to the currently anticipated FDA review timing. Primary study results are expected to be published following completion of the review. Announcement no. 07/2026 | 18 August 2026 8 0.8 billion Reported revenue in DKK for Q3 2025/26 8% 7% 9M 2025/26 Q3 2025/26 Organic growth 8% 4% Organic growth Acquisition operations Exchange rates Reported growth Reported growth 4% 8% 9M 2025/26 Q3 2025/26 9M Growth compo- sition (9 mths) 1% Acute Care -4% 1. Coloplast’s Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of men. 2. Investigational device currently under development. Not cleared or approved for sale in U.S. or any market. 3. Randomized, Sham-Controlled, Double-Blind Trial of the Intibia System in Urge Urinary Incontinence: Quality-of-Life Outcome
Page 9
Earnings Gross profit Gross profit was DKK 14,360 million, compared to DKK 14,183 million last year, corresponding to a gross margin of 67%, compared to 68% last year. The gross margin was negatively impacted by currencies of around 90 basis points, mostly related to the depreciation of the USD, GBP, and a basket of Emerging markets currencies against the DKK, and appreciation of the HUF against the DKK. Ramp-up costs in Costa Rica and Portugal also impacted the gross margin negatively. The negative impact was partly offset by lower inflation on freight compared to last year. In Q3, gross profit was DKK 4,908 million, corresponding to a Q3 gross margin of 67% compared to 68% for the same period last year. The Q3 gross margin was impacted by the above-mentioned drivers and around 150 basis points negative impact from currencies. The conflict in the Middle East did not have any material impact on the gross margin in Q3. Costs Operating expenses amounted to DKK 8,761 million, a DKK 296 million (3%) increase from last year. Operating expenses in Q3 amounted to DKK 2,979 million, a DKK 189 million (7%) increase from last year. Distribution costs amounted to DKK 7,069 million, a DKK 171 million (2%) increase from DKK 6,898 million last year. The increase reflects Kerecis one- off costs in Q1, lower sales costs in China (following the organisational restructuring last year), and lower logistic costs (due to one-off costs last year related to the new US distribution centre). The development in distribution costs was also positively impacted by the depreciation of the USD against the DKK. Distribution costs amounted to 33% of revenue, on par with last year. In Q3, distribution costs amounted to DKK 2,400 million, or 33% of revenue, a similar level to Q3 last year. Administrative expenses amounted to DKK 964 million, up DKK 34 million (4%) from DKK 930 million last year, and includes around DKK 15 million in one- off advisory costs incurred by Kerecis in Q1 in connection with the recent CMS regulatory changes in the US out-patient setting. Administrative expenses accounted for 4% of revenue, on par with last year. The Q3 administrative expenses amounted to DKK 323 million or 4% of revenue, against 5% last year. The R&D costs were DKK 782 million, compared to DKK 697 million last year, a DKK 85 million (12%) increase. The increase was driven by higher activity levels in Chronic Care and Kerecis. R&D costs amounted to 4% of revenue, compared to 3% last year. The Q3 R&D costs amounted to DKK 281 million, or 4% of revenue, compared to 3% last year. Other operating income and other operating expenses amounted to a net income of DKK 54 million against a net income of DKK 60 million last year. Operating profit before interest, tax, depreciation and amortisation (EBITDA) and before special items EBITDA before special items amounted to DKK 6,656 million, a DKK 77 million (1%) decrease from DKK 6,733 million last year. The EBITDA margin before special items was 31%, compared to 32% last year. In Q3, EBITDA before special items was DKK 2,291 million, a DKK 33 million (1%) increase from Q3 last year. The EBITDA margin before special items was 31% in Q3, down from 32% last year. Operating profit (EBIT) before special items EBIT before special items amounted to DKK 5,599 million, a DKK 119 million (2%) decrease from DKK 5,718 million last year. The EBIT margin before special items was 26%, compared with 27% last year, reflecting around 90 basis points negative impact from currencies (mostly related to the depreciation of the USD, Announcement no. 07/2026 | 18 August 2026 9 Income statement, DKK millions 2025/26 Index Revenue 21,482 103 Production costs -7,122 106 Gross profit 14,360 101 Distribution costs -7,069 102 Administrative expenses -964 104 Research and development costs -782 112 Other operating income 80 90 Other operating expenses -26 91 Operating profit (EBIT) before special items 5,599 98 Special items -3,078 N/A Operating profit (EBIT) 2,521 46 Financial income 484 575 Financial expenses -584 61 Profit before tax 2,421 53 Tax on profit for the period -533 29 Net profit for the period 1,888 68
Page 10
GBP, and a basket of Emerging markets currencies against the DKK, as well as appreciation of the HUF against the DKK) and around 50 basis points negative impact from Kerecis. In constant currencies, EBIT grew 5% compared to last year. In Q3, EBIT before special items was DKK 1,929 million, a DKK 14 million (1%) increase from last year. The EBIT margin before special items was 26% in Q3, against 28% last year, and included around 110 basis points negative impact from currencies and around 60 basis points negative impact from Kerecis. In constant currencies, EBIT grew 5% compared to last year. Special items Coloplast incurred special items expenses of DKK 3,078 million in the first nine months of the year, of which DKK 3,000 million relates to the recognition of Kerecis impairment loss as a result of the sales disruption from the Medicare reimbursement change in the out-patient setting and the slower market recovery now anticipated. Furthermore DKK 60 million was incurred in integration costs related to Atos Medical and Kerecis, and DKK 18 million in acquisition costs related to Uromedica. Special items in Q3 amounted to DKK 18 million, with DKK 15 million related to integration activities and DKK 3 million in acquisition-related costs. Operating profit (EBIT) after special items EBIT after special items was DKK 2,521 million, a DKK 2,956 million (54%) decrease from last year. The EBIT margin after special items was 12%, compared to 26% last year. The Q3 EBIT after special items was DKK 1,911 million, a DKK 79 million (4%) increase from last year, with an EBIT margin of 26%. Financial items and tax Financial items were a net expense of DKK 100 million against a net expense of DKK 875 million last year. The net expense included interest expenses of DKK 472 million, compared to DKK 566 million last year, mostly related to the financing of the Atos Medical acquisition. The financial expenses were largely offset by gains on exchange rate adjustments, of which DKK 290 million were gains on balance sheet items, mostly related to the USD, CRC and HUF, and DKK 119 million were realised gains on cash flow hedges, mostly related to the USD and HUF. The Q3 financial items were a net expense of DKK 37 million compared to a net expense of DKK 490 million in the same period last year. The lower expense this year was mainly driven by gains on balance sheet items (mostly related to the USD, CRC and HUF), compared with losses on balance sheet items in Q3 last year. The tax expense in the first nine months of 2025/26 was DKK 533 million, compared to an ordinary tax expense of DKK 1,012 million last year and a total tax expense of DKK 1,841 million last year (the total tax expense last year included a non-recurring expense of DKK 829 million related to the transfer of Kerecis’ Intellectual Property (IP) from Iceland to Denmark, consistent with Coloplast’s operating model). The tax rate was 22%, on par with the ordinary tax rate last year. Net profit Net profit before special items was DKK 4,289 million, a DKK 1,339 increase from 2,949 million last year, as last year’s result was negatively impacted by the non-recurring tax expense related to the Kerecis IP transfer. Diluted earnings per share (EPS) before special items were DKK 19.03, or a 45% increase from last year. Adjusted for the non-recurring tax impact last year, net profit before special items increased DKK 510 million and adjusted diluted EPS before special items increased by 14%. Net profit after special items was DKK 1,888 million and diluted EPS after special items were DKK 8.38. The Q3 net profit before special items amounted to DKK 1,476 million, against DKK 870 million last year. The diluted Q3 earnings per share (EPS) before special items were DKK 6.55. Adjusted for the non-recurring tax impact in Q3 last year, the adjusted net profit before special items increased DKK 364 million, and adjusted diluted EPS before special items increased by 33%. The Q3 net profit after special items was DKK 1,462 million and diluted earnings per share (EPS) after special items were DKK 6.49. Announcement no. 07/2026 | 18 August 2026 10
Page 11
Cash flows and investments Cash flows from operating activities Cash flows from operating activities amounted to an inflow of DKK 5,409 million, against an inflow of DKK 4,380 million last year. The positive development in cash flows from operating activities was mostly driven by changes in working capital, in particular due to improved trade receivables. Lower net financial items also had a positive impact on cash flows, while higher income tax paid had a negative impact. Investments Net investments amounted to DKK 1,316 million in the first nine months of 2025/26, compared with DKK 861 million last year. The increase reflects higher capital expenditures and impact from the acquisition of Uromedica (DKK 139 million). The increase also reflects a low baseline, due to the divestment of the Skin Care business last year (DKK 192 million). Capital expenditures amounted to DKK 1,159 million in the first nine months of 2025/26, or 5% of revenue, on par with last year. Capital expenditures related to the new manufacturing site in Portugal (on track to be operational in Q4 2025/26) comprised 1% of revenue. Innovation capex likewise comprised 1% of revenue. Free cash flow As a result, the free cash flow was an inflow of DKK 4,093 million, compared to an inflow of DKK 3,519 million last year, or a 16% increase. Excluding acquisition costs this year and benefit from the divestment last year, the free cash flow increased 27% in the first nine months of 2025/26. The free cash flow-to-sales ratio was 20%, compared to 16% last year (excluding acquisition costs this year and benefit from the divestment last year). Capital resources At 30 June 2026, Coloplast had net interest-bearing debt of DKK 22,986 million, against DKK 21,692 million at 30 September 2025. The gearing ratio at the end of the period was 2.6x EBITDA (before special items). Statement of financial position and equity Balance sheet At 30 June 2026, total assets amounted to DKK 46,938 million, a decrease of DKK 1,429 million compared to 30 September 2025. Working capital was 26% of revenue, on par with 30 September 2025. Inventories increased by DKK 212 million to DKK 4,131 million, trade payables increased by DKK 39 million to DKK 1,363 million and trade receivables increased by DKK 9 million to DKK 4,667 million. The working capital-to-sales ratio for the financial year 2025/26 is still expected to be around 25%. In the Impact4 strategic period the working capital-to- sales ratio is expected to improve to around 24%. Equity Equity decreased by DKK 2.8 billion to DKK 13,367 million, compared to 30 September 2025. Total comprehensive income for the period of DKK 2,399 million and share-based remuneration of DKK 71 million were offset by payment of dividends of DKK 5,184 million. Treasury shares At 30 June 2026, Coloplast’s holding of treasury shares consisted of 2,831,862 B shares, which was 1,342 less than 30 September 2025. Return on invested capital (ROIC) ROIC after tax and before special items was 15%, on par with last year (adjusted for the impact from the Kerecis IP transfer last year). Announcement no. 07/2026 | 18 August 2026 11
Page 12
Update on sustainability strategy and performance 9M 9M FY Priority Unit Impact4 ambition 2025/26 2024/25 Change 2024/25 Net Zero by 2045 Scope 1 and 2 emissions1) 2) % reduction 90% reduction by 2030 38 % 33 % 5%-p 41 % Renewable energy use3) % of total 100% 88 % 87 % 1%-p 69 % Electric company cars4) % of total 100% by 2030 – – – 16 % Scope 3 emissions2) 4) % reduction per product 10% reduction by 2030 – – – -10 % Business travel by air4) % reduction 10% reduction – – – 61 % Goods transported by air4) % of total < 5% of total – – – 3 % Positively impact people Users & HCPs5) Numbers of markets Reimbursement improve- ments in 5 markets – – – – Lost time injury frequency6) Parts per million 1.5 by 2030 1.9 1.7 0.2 1.7 Code of Conduct training4) % of white collars 100% – – – 99 % Diversity in leadership7) % of total 40% by 2030 27 % – – 26 % Employee satisfaction8) Engagement score Above benchmark9) 78 % – – – All measurements reported above are consistent with the definition per E1-5 in CSRD. Comparison figures for 9M 2024/25 and full year 2024/25 have been updated to reflect this methodology. Scope 1 and 2 emissions The absolute scope 1 and 2 emissions decreased by 38% in 9M 2025/26, compared to the base year 2018/19, a notable improvement compared to last year at 33%. The reduction in absolute scope 1 and 2 emissions was positively impacted by the continued phase-out of natural gas and energy efficiency improvements. Renewable energy use increased to 88% of the total energy use in 9M 2025/26, compared to 87% last year, driven by the above-mentioned drivers. Coloplast has initiated several renewable energy projects, expected to materialise during the Impact4 strategic period. Lost time injury frequency The lost time injury (LTI) frequency in 9M 2025/26 was 1.9 ppm, compared to 1.7 ppm last year. Coloplast continues to work on reducing LTIs and have set activities in motion to ensure a safe work environment for all employees. Employee engagement survey Coloplast’s annual employee survey conducted in May showed a high level of employee satisfaction with an engagement score of 78%, above industry benchmark9. ESG Ratings Sustainalytics ranking 2026 Coloplast received Sustainalytics ranking of 17.1, and hence maintains a ‘low risk’ score. Announcement no. 07/2026 | 18 August 2026 12 1) 9M 24/25 Scope 1&2 numbers changed due to restatement of base year. 2) From base year 2018/19. 3) Energy consumption of sites, excluding cars. 4) Metric will only be reported on a semi-annual or full-year basis. 5) New Sustainability target under Impact4. FY 2025/26 is the first reporting year, disclosed at year-end. 6) Four quarters rolling average. 7) Continuation of the former target ‘Female senior leaders (VP+ level)’. 8) New methodology for the employee engagement survey; results are incomparable to prior periods. 9) Industry benchmark of 74% (top 50% - Healthcare).
Page 13
Other matters CEO's first 100 days: priorities for the next phase of Impact4 Following the CEO transition on May 1, President & CEO Gavin Wood has spent his first 100 days close to the business, developing a perspective on the opportunities, priorities and choices that will be central to driving long-term value creation. Five priorities stand out: 1) Sustain the strength and power of Chronic Care Chronic Care is the foundation of Coloplast and the principal engine of the Group’s growth, profitability and cash generation. Looking ahead, focus will be to extend our leadership through i) increased investment in innovation with accelerated time-to-market, and ii) strong commercial execution - both anchored in deep customer-centricity. 2) Increase focus on US opportunity The US remains the biggest market and value creation opportunity for the Group. While the Group holds leading positions across Chronic Care globally, we see significant potential to further strengthen our position in the US. Similarly, we see considerable potential to grow our Men’s Health business in the US, the fastest-growing part of Interventional Urology. Going forward, this means placing greater emphasis on accelerating growth in the US through focused investments in innovation, strengthened commercial execution, and disciplined resource and capital allocation to the US. 3) Accelerate Wound & Tissue Repair Our conviction in the long-term Biologics opportunity remains intact. The market reset in US Biologics has accelerated our learnings and created greater clarity on the customer segments, specialties and care settings, where Coloplast is best positioned to win. Looking ahead, we are prioritising the in- patient setting, where we see the center of gravity in biologics shifting. This is a market where Kerecis’ clinical evidence and clear differentiation provide a strong right to win, and where we will focus resources on strong penetration of priority accounts and specialty-led growth. Priority over the coming quarters will likewise be to restore profitable growth in the biologics business through improved field productivity and scaling clinical expertise. After three decades in the global healthcare industry, Fertram Sigurjonsson will transition from his role as Executive Vice President of Wound & Tissue Repair and member of the Executive Leadership Team into a new strategic role at Coloplast as Chief Innovation & Technology Advisor to the CEO. Gavin Wood will assume leadership of the global Wound & Tissue Repair business on an interim basis. 4) Fund growth through continuous improvement and focused capital deployment Coloplast has built a strong track record of operational discipline and cost management, driving continuous productivity and efficiency improvements and underpinning its industry-leading profitability. Delivering on the priorities outlined above will require an even sharper focus on resource allocation, capital deployment and investment governance, ensuring resources are directed towards the opportunities with the greatest potential to drive growth and value creation. 5) Evolve our culture and people agenda Coloplast is a purpose-driven organisation with strong values and customer focus. Looking ahead, we will build on this foundation by driving performance excellence, evolving critical capabilities, creating an environment where people and teams can perform at their best, and ensuring we have the strongest talent in the roles most critical to executing our strategy. An important first step has been the appointment of Amanda Rajkumar, as Coloplast’s new Chief People Officer, effective September 1, 2026. Looking ahead The CEO's first 100 days have helped identify the choices to be made in order to drive long-term value creation. At the full-year 2025/26 results, management expects to provide a broader update on the implications for our strategic priorities, value drivers and execution within the Impact4 framework. Announcement no. 07/2026 | 18 August 2026 13
Page 14
Impact4 financial ambition Organic growth of 7-8% (5-year CAGR) EBIT growth in line with or above revenue growth over the period In constant currencies, before special items Return on Invested Capital of more than 20% in 2029/30. After tax, before special items. Linear improvement expected over the period. Capex-to-sales ratio around 4-5% Effective tax rate around 22% Net debt/EBITDA ratio is expected to decrease to around 1.5x towards FY 2029/30. Key assumptions Current macroeconomic, geopolitical and industry-specific developments, including US tariffs and regulatory changes, are continuously monitored and their potential impact on our business is evaluated on an ongoing basis. As such, the financial guidance is subject to a higher degree of uncertainty due to the changing environment. The addressable market in which Coloplast operates is expected to continue growing at 4-5%. Revenue growth Organic growth is expected to be 5-6% in constant currencies with the following assumptions: a. Chronic Care: – Continued good momentum ex. China. - China sales expected to decline high single-digit including impact from the planned inventory reduction in H2. b. Wound & Tissue Repair: - Kerecis – organic growth expected to be around 0%, due to the Medicare reimbursement change in the out- patient setting. - Advanced Wound Dressings – negative impact from the product return in China in Q1-Q3 and softer momentum in Europe. c. Interventional Urology – high single- digit growth. Reported growth in DKK is expected to be around 3%, with 2-3%-points negative impact from currencies. The skin care divestment and Uromedica acquisition are combined expected to have a broadly neutral impact on the reported revenue growth. EBIT growth The EBIT growth in constant currencies before special items is expected to be around 5% with the following assumptions: a. Continued ramp-up in Costa Rica and Portugal. b. New Impact4 investments, including global technology investments, investments toward the new bowel care opportunity in the US, and investments related to Intibia™. c. Kerecis EBIT margin of around 0%. d. Immaterial impact from tariffs, as we expect our products to remain exempted. Coloplast is closely monitoring developments in the Middle East and their impact on the business, including implications for demand, supply and cost inflation. The Group’s revenue exposure to the region is limited, representing approximately 1–2% of Group revenues. Return on Invested Capital after tax, before special items is expected around 15%. Special items expected to be around DKK 3.1 billion and includes DKK 3 billion Kerecis impairment loss and around DKK 0.1 billion in acquisition related cost, including integration costs. Capex-to-sales ratio is expected to be around 5% and includes investments to complete the new manufacturing site in Portugal, investments in new machines for existing and new products, IT and sustainability investments. The effective tax rate is expected to be around 22%. Dividend policy The Board of Directors intends to distribute excess liquidity to the shareholders through dividends and share buybacks, with a target payout ratio of 60-80% of net profit. Announcement no. 07/2026 | 18 August 2026 14 2025/26 Financial guidance 5-6% Organic revenue growth at constant exchange rates Around 5% EBIT growth at constant exchange rates, before special items Around 15% Return on Invested Capital after tax, before special items Around 5% Capex-to-sales ratio Around 22% Effective tax rate
Page 15
Forward-looking statements The forward-looking statements in this announcement, including revenue and earnings guidance, do not constitute a guarantee of future results and are subject to risk, uncertainty and assumptions, the consequences of which are difficult to predict. The forward-looking statements are based on our current expectations, estimates and assumptions and are provided on the basis of information available to us at the present time. Major fluctuations in the exchange rates of key currencies, significant changes in the healthcare sector or major developments in the global economy may impact our ability to achieve the defined long-term targets and meet our guidance. This may impact our company’s financial results. Exchange rate exposure Our financial guidance for the 2025/26 financial year has been prepared on the basis of the following assumptions for the company’s principal currencies: OVERVIEW OF EXCHANGE RATES FOR KEY CURRENCIES AGAINST DKK GBP USD HUF Average exchange rate 9M 2024/25 889 689 1.84 Average exchange rate 9M 2025/26 859 641 1.98 Change in average exchange rates for 2025/26 compared with the same period last year -3 % -7 % 8 % Average exchange rate 2024/251⁾ 882 676 1.85 Spot rate on 14 August 2026 875 647 2.06 Estimated average exchange r a t e 2 0 2 5 / 2 6 ² ⁾ 863 643 2.00 Change in estimated average exchange rates compared with average exchange rate 2024/25 -2 % -5 % 8 % ¹ ⁾ A v e r a g e e x c h a n g e r a t e s f o r 2 0 2 4 / 2 5 a r e from 1 October 2024 to 30 September 2025. ² ⁾ E s t i m a t e d a v e r a g e e x c h a n g e r a t e s a r e calculated as the average exchange rates for the first nine months combined with the spot rates at 14 August 2026. Revenue is particularly exposed to developments in USD and GBP relative to DKK. Fluctuations in HUF against DKK impact the operating profit because a substantial part of our production, and thus of our costs, are in Hungary, whereas our sales in the market are limited. EFFECT OVER 12 MONTHS OF A 10% INITIAL DROP IN EXCHANGE RATES FOR KEY CURRENCIES (DKK MILLION) Revenue EBIT USD -740 -290 GBP -400 -240 HUF – 160 Announcement no. 07/2026 | 18 August 2026 15
Page 16
Statement by the Board of Directors and the Executive Management The Board of Directors and the Executive Management have today considered and approved the interim report of Coloplast A/S for the period 1 October 2025 – 30 June 2026. The interim report which has neither been audited nor reviewed by the company’s auditors, is presented in accordance with IAS 34 “Interim financial reporting” as adopted by the EU and additional Danish disclosure requirements for interim reports of listed companies. In our opinion, the interim report gives a true and fair view of the Group’s assets, liabilities and financial position at 30 June 2026 and of the results of the Group’s operations and cash flows for the period 1 October 2025 – 30 June 2026. Furthermore, in our opinion, the Management’s report includes a fair account of the development and performance of the Group, the results for the period and of the financial position of the Group. Other than set forth in the interim report, no changes have occurred to the significant risks and uncertainty factors compared with those disclosed in the annual report for 2024/25. Humlebæk, 18 August 2026 Executive Management Gavin Wood Anders Lonning-Skovgaard President, CEO Executive Vice President, CFO Board of Directors Jette Nygaard-Andersen Niels Peter Louis-Hansen Niels B. Christiansen Interim Chair Deputy Chairman Carsten Hellmann Annette Brüls Marianne Wiinholt Thomas Barfod Roland V. Pedersen Nikolaj Kyhe Gundersen Elected by the employees Elected by the employees Elected by the employees Announcement no. 07/2026 | 18 August 2026 16
Page 17
Statement of comprehensive income 1 October - 30 June, unaudited Consolidated 2025/26 2024/25 2025/26 2024/25 DKK million Note 9 mths 9 mths Index Q3 Q3 Index Revenue 2 21,482 20,914 103 7,355 6,958 106 Production costs -7,122 -6,731 106 -2,447 -2,253 109 Gross profit 14,360 14,183 101 4,908 4,705 104 Distribution costs -7,069 -6,898 102 -2,400 -2,243 107 Administrative expenses -964 -930 104 -323 -335 97 Research and development costs -782 -697 112 -281 -239 117 Other operating income 80 89 90 39 38 104 Other operating expenses -26 -29 91 -14 -11 133 Operating profit (EBIT) before special items 5,599 5,718 98 1,929 1,915 101 Special items 3 -3,078 -241 >100 -18 -83 >100 Operating profit (EBIT) 2,521 5,477 46 1,911 1,832 104 Financial income 4 484 84 575 169 -75 -226 Financial expenses 4 -584 -959 61 -206 -415 50 Profit before tax 2,421 4,602 53 1,874 1,342 140 Tax on profit for the period -533 -1,841 29 -412 -537 77 Net profit for the period 1,888 2,761 68 1,462 805 182 Remeasurements of defined benefit plans 5 -4 -2 -3 Tax on remeasurements of defined benefit plans -1 – 1 – Items that will not be reclassified to the income statement 4 -4 -1 -3 Value adjustment of currency hedging -89 128 11 201 Recycle through the income statement -175 18 -4 -34 Tax effect of hedging 58 -32 -2 -37 Currency adjustment of opening balances and other value adjustments relating to subsidiaries 713 771 164 -77 Tax effect of currency adjustment, assets in foreign currency – -254 – -254 Items that may be reclassified to income statement 507 631 169 -201 Total other comprehensive income 511 627 168 -204 Total comprehensive income 2,399 3,388 1,630 601 DKK Earnings per share (EPS) 8.38 12.25 6.49 3.57 Earnings per share (EPS), diluted 8.38 12.25 6.49 3.57 Announcement no. 07/2026 | 18 August 2026 17
Page 18
Statement of cash flows 1 October - 30 June, unaudited Consolidated 2025/26 2024/25 DKK million Note 9 mths 9 mths Operating profit 2,521 5,477 Amortisation and impairment 3,379 369 Depreciation 678 646 Adjustment for other non-cash operating items 6 83 113 Changes in working capital 6 -345 -977 Ingoing interest payments, etc. 138 27 Outgoing interest payments, etc. -504 -830 Income tax paid -541 -445 Cash flows from operating activities 5,409 4,380 Investments in intangible assets -123 -98 Investments in land and buildings -2 -6 Investments in plant and machinery and other fixtures and fittings, tools and equipment -64 -55 Investments in property, plant and equipment under construction -970 -877 Property, plant and equipment sold 11 4 Investment in other investments -29 -21 Company divestment – 192 Acquisition of a subsidiary, net of cash acquired 9 -139 – Cash flows from investing activities -1,316 -861 Free cash flow 4,093 3,519 Dividend to shareholders -5,183 -4,958 Sale of treasury shares and loss on exercised options – 27 Financing from shareholders -5,183 -4,931 Repayment of lease liabilities -216 -212 Financing through debt funding 840 – Movements on credit facilities 303 1,600 Cash flows from financing activities -4,256 -3,543 Net cash flows -163 -24 Cash and cash equivalents at 1 October 947 788 Foreign exchange value adjustments 30 -38 Cash and cash equivalents, acquired operations 3 – Net cash flows -163 -24 Cash and cash equivalents at 30 June 7 817 726 The cash flow statement cannot be derived using only the published financial data. Announcement no. 07/2026 | 18 August 2026 18
Page 19
Assets At 30 June, unaudited Consolidated DKK million Note 30.06.2026 30.06.2025 30.09.2025 Intangible assets 27,335 29,916 29,811 Property, plant and equipment 7,193 5,946 6,201 Right-of-use assets 902 894 884 Other equity investments 119 95 90 Deferred tax asset 672 448 587 Income tax 294 – 316 Other receivables 26 25 25 Non-current assets 36,541 37,324 37,914 Inventories 4,131 3,777 3,919 Trade receivables 4,667 4,789 4,658 Income tax 47 404 64 Other receivables 353 543 454 Prepayments 382 317 411 Cash and cash equivalents 817 726 947 Current assets 10,397 10,556 10,453 Assets 46,938 47,880 48,367 Announcement no. 07/2026 | 18 August 2026 19
Page 20
Equity and liabilities At 30 June, unaudited Consolidated DKK million Note 30.06.2026 30.06.2025 30.09.2025 Share capital 228 228 228 Currency translation reserve -1,444 -1,036 -2,137 Reserve for currency hedging 150 443 356 Proposed ordinary dividend for the period – – 4,057 Retained earnings 14,433 16,813 13,618 Equity 13,367 16,448 16,122 Provisions for pensions and similar liabilities 118 136 111 Deferred tax liability 3,187 2,609 3,042 Other provisions 253 21 25 Bonds 5 11,585 11,564 11,570 Other credit institutions 8,622 5,000 7,783 Income tax 2,422 829 2,488 Other payables 1 1 19 Lease liabilities 717 712 696 Prepayments 6 7 6 Non-current liabilities 26,911 20,879 25,740 Provisions for pensions and similar liabilities 7 5 8 Other provisions 67 47 51 Other credit institutions 2,627 6,685 2,328 Trade payables 1,363 1,186 1,324 Income tax 164 1,354 149 Other payables 2,179 1,021 2,382 Lease liabilities 252 254 262 Prepayments 1 1 1 Current liabilities 6,660 10,553 6,505 Equity and liabilities 46,938 47,880 48,367 Announcement no. 07/2026 | 18 August 2026 20
Page 21
Statement of changes in equity, current year At 30 June, unaudited Consolidated Share capital Reserves DKK million A shares B shares Currency translation Currency hedging Proposed dividend Retained earnings Total 2025/26 Equity at 1 October 18 210 -2,137 356 4,057 13,618 16,122 Net profit for the period – – – – 1,127 761 1,888 Other comprehensive income – – 693 -206 – 24 511 Total comprehensive income – – 693 -206 1,127 785 2,399 Share-based payment – – – – – 71 71 Tax on share-based payment, etc. – – – – – -41 -41 Interim dividend paid out in respect of 2025/26 – – – – -1,127 – -1,127 Dividend paid out in respect of 2024/25 – – – – -4,057 – -4,057 Transactions with shareholders – – – – -5,184 30 -5,154 Equity at 30 June 2026 18 210 -1,444 150 – 14,433 13,367 Announcement no. 07/2026 | 18 August 2026 21
Page 22
Statement of changes in equity, last year At 30 June, unaudited Consolidated Share capital Reserves DKK million A shares B shares Currency translation Currency hedging Proposed dividend Retained earnings Total 2024/25 Equity at 1 October 18 210 -1,837 329 3,831 15,391 17,942 Net profit for the period – – – – 1,127 1,634 2,761 Other comprehensive income – – 801 114 – -288 627 Total comprehensive income – – 801 114 1,127 1,346 3,388 Sale of treasury shares and loss on exercised options – – – – – 27 27 Share-based payment – – – – – 62 62 Tax on share-based payment, etc. – – – – – -13 -13 Interim dividend paid out in respect of 2024/25 – – – – -1,127 – -1,127 Dividend paid out in respect of 2023/24 – – – – -3,831 – -3,831 Transactions with shareholders – – – – -4,958 76 -4,882 Equity at 30 June 18 210 -1,036 443 – 16,813 16,448 Announcement no. 07/2026 | 18 August 2026 22
Page 23
List of notes Key accounting policies 1 Accounting policies Profit and loss 2 Segment information 3 Special items 4 Financial income and expenses Assets and liabilities 5 Bonds Cash flows 6 Specifications of cash flow from operating activities 7 Cash and cash equivalents Other disclosures 8 Contingent liabilities 9 Acquisition 10 Impairment Announcement no. 07/2026 | 18 August 2026 23
Page 24
Note 1 Accounting policies The unaudited interim report is presented in accordance with IAS 34 “Interim financial reporting” as adopted by the EU and additional Danish disclosure requirements for interim reports of listed companies. The accounting policies for recognition and measurement applied in the preparation of the interim report are consistent with those applied in the Annual Report 2024/25. Note 2 Segment information Operating segments The operating segments are defined on the basis of the monthly reporting to the Executive Leadership Team, which is considered the senior operational management and the management structure. Reporting to the Executive Leadership Team is based on five operating segments: Chronic Care, Voice & Respiratory Care, Interventional Urology, Advanced Wound Dressings and Biologics. The segment Chronic Care covers the sale of ostomy care products and continence care products. The segment Voice & Respiratory Care covers the sale of laryngectomy and tracheostomy products. The segment Interventional Urology covers the sale of urological products, including disposable products. The segment Advanced Wound Dressings covers the sale of Advanced Wound Dressings, Skin Care and contract manufacturing. The segment Biologics covers tissue-based products. The segmentation reflects the structure of reporting to the Executive Leadership Team. The shared/non-allocated costs comprises support functions (production units and staff functions) and eliminations, as these functions do not generate revenue. While the costs of R&D for Interventional Urology, Voice & Respiratory Care and Biologics are included in the segment operating profit/loss for the above-mentioned segments, R&D activities for Chronic Care and Advanced Wound Dressings are shared functions which are included in shared/non-allocated functions. The shared/non-allocated costs also include PPA amortisation expenditures related to Voice & Respiratory Care and Biologics. Financial items and income tax are not allocated to the operating segments. The Executive Leadership Team reviews each operating segment separately, applying their market contributions to earnings and allocating resources on that basis. The market contribution is defined as external revenue less the sum of direct production costs, distribution costs, sales costs, marketing costs and administrative expenses. Costs are allocated directly to segments. Certain immaterial indirect costs are allocated systematically to the shared/non-allocated and the reporting segments. The Executive Leadership Team does not receive reporting on assets and liabilities by the reporting segments. Accordingly, the reporting segments are not measured in this respect, nor do we allocate resources on this background. No single customer accounts for more than 10% of revenue. Announcement no. 07/2026 | 18 August 2026 24
Page 25
Note 2, continued DKK million Chronic Care Voice & Respiratory Care Interventional Urology Advanced Wound Dressings Biologics Group 2025/26 Segment revenue: Ostomy Care 7,599 – – – – 7,599 Continence Care 6,989 – – – – 6,989 Voice & Respiratory Care – 1,788 – – – 1,788 Interventional Urology – – 2,212 – – 2,212 Wound & Tissue Repair – – – 2,029 865 2,894 External revenue as per the statement of comprehensive income 14,588 1,788 2,212 2,029 865 21,482 Costs allocated to segment -6,041 -1,163 -1,414 -1,210 -878 -10,706 Segment operating profit/loss 8,547 625 798 819 -13 10,776 Shared/non-allocated -5,177 Special items not included in segment operating profit/loss (see note 3) -3,078 Operating profit before tax (EBIT) as per the statement of comprehensive income 2,521 Net financials -100 Tax on profit/loss for the period -533 Profit/loss for the period as per the statement of comprehensive income 1,888 DKK million Chronic Care Voice & Respiratory Care Interventional Urology Advanced Wound Dressings Biologics Group 2024/25 Segment revenue: Ostomy Care 7,415 – – – – 7,415 Continence Care 6,672 – – – – 6,672 Voice & Respiratory Care – 1,706 – – – 1,706 Interventional Urology – – 2,117 – – 2,117 Wound & Tissue Repair – – – 2,089 915 3,004 External revenue as per the statement of comprehensive income 14,087 1,706 2,117 2,089 915 20,914 Costs allocated to segment -5,851 -1,076 -1,380 -1,201 -803 -10,311 Segment operating profit/loss 8,236 630 737 888 112 10,603 Shared/non-allocated -4,884 Special items not included in segment operating profit/loss (see note 3) -241 Operating profit before tax (EBIT) as per the statement of comprehensive income 5,477 Net financials -875 Tax on profit/loss for the period -1,841 Profit/loss for the period as per the statement of comprehensive income 2,761 Announcement no. 07/2026 | 18 August 2026 25
Page 26
Note 3 Special items DKK million 2025/26 2024/25 Integration activities related to Atos and Kerecis 60 60 Acquisition related costs 18 – Costs related to structural changes – 112 Skin Care divestment – -11 Impairment loss, Kerecis goodwill 3,000 – Executive leadership team severance costs – 80 Total 3,078 241 In the first nine months of 2025/26 special items contain expenses related to a non-cash impairment loss of DKK 3.0 billion related to goodwill arising from the acquisition of Kerecis. For further details on the impairment please refer to note 10. Furthermore special items contain expenses related to integration costs for the Atos Medical and Kerecis acquisitions, and the acquisition cost of Uromedica, acquired on 18 of February 2026. Last year’s special items contain expenses related to integration costs for the Atos Medical and Kerecis acquisitions, as well as cost for structural changes, the divestment of the skin care business and Executive leadership team severance costs. Note 4 Financial income and expenses DKK million 2025/26 2024/25 Financial income Interest income 19 24 Fair value adjustments of forward contracts transferred from other comprehensive income 119 – Fair value adjustments of cash-based share options – 2 Interest hedges 56 56 Net exchange adjustments 290 – Other financial income – 2 Total 484 84 Financial expenses Interest expenses 252 347 Capitalised borrowing cost -10 -6 Interest expenses, lease liabilities 32 29 Interest expenses, bonds 220 219 Fair value adjustments of forward contracts transferred from other comprehensive income – 74 Net exchange adjustments – 208 Hyperinflationary adjustment of monetary position 29 36 Other financial expenses and fees 61 52 Total 584 959 Announcement no. 07/2026 | 18 August 2026 26
Page 27
Note 5 Bonds Bonds Coloplast has outstanding senior unsecured notes in an aggregate principal amount of EUR 1.5 billion under the Coloplast Euro Medium Term Note programme. The Notes are unconditionally and irrevocably guaranteed by Coloplast. COLOCB2 and COLOCB3 carries a fixed coupon until expiry date. COLOCB2 and COLOCB3 can be redeemed at a market price fixed on the redemption date in relation to named EUR bonds with similar maturity. A pre-hedge was made in 2021/22 with Interest swaps on COLOCB2 and COLOCB3 with mandatory breakage on the day the bonds are issued to limit the financial risks. The gain of DKK 521 million has as per hedge accounting been set off in the equity and transferred to the financial items during the lifetime of the bonds. Short name Currency Amount, million Expiry date Coupon COLOCB2 EUR 850 19-05-2027 2.25 COLOCB3 EUR 700 19-05-2030 2.75 Note 6 Specifications of cash flow from operating activities DKK million 2025/26 2024/25 Net gain/loss on divestment of non-current assets -4 47 Change in other provisions 37 5 Other non-cash operating items 50 61 Adjustment for other non-cash operating items 83 113 Inventories -53 -265 Trade receivables 56 -262 Other receivables, including amounts held in escrow 142 -85 Trade and other payables etc. -490 -365 Changes in working capital -345 -977 Announcement no. 07/2026 | 18 August 2026 27
Page 28
Note 7 Cash and cash equivalents DKK million 2026 2025 Bank deposits, short term 817 726 Cash and cash equivalents at 30 June 817 726 Note 8 Contingent liabilities The Coloplast Group is a party to a few minor legal proceedings, which are not expected to influence the Group’s future earnings. The company has certain future milestone payment related to historical business acquisitions that may become due in the future. Note 9 Acquisitions On 18 February 2026, Coloplast completed the acquisition of all shares and voting rights of Uromedica. Strategic rationale Uromedica is a medical technology company specialising in the treatment of stress urinary incontinence. The transaction strategically strengthens Coloplast’s presence within men’s health in Interventional Urology. The acquisition expands Coloplast’s product and technology offering in this segment and supports future regulatory and commercial development. Transaction costs Coloplast has, during the 2025/26 financial year, incurred transaction costs relating to the acquisition of approximately DKK 18 million, which have been recognised under special items in the statement of comprehensive income. Purchase price and contingent consideration The agreed consideration for the acquisition consists of an upfront cash payment and a contingent consideration. The upfront cash consideration amounted to DKK 139 million, which fell due for payment at the acquisition date. In addition, a contingent consideration of DKK 210 million has been recognised at fair value (level 3) at the acquisition date as a financial liability. The contingent consideration is dependent on the achievement of future regulatory and commercial milestones. Subsequent changes in the fair value of the contingent consideration are recognised in the consolidated income statement. Fair value of acquired net assets and recognised goodwill The fair value of the acquired net assets has been identified and goodwill recognised. The initial accounting for the acquisition remains provisional as the Group is still finalising certain elements of the purchase price allocation, including the valuation of acquired intangible assets, related deferred tax effects and contingent consideration. During Q3 2025/26, the provisional purchase price allocation was updated based on further information obtained regarding facts and circumstances that existed as of the acquisition date. The update primarily resulted in an increase in deferred tax liabilities from DKK 42 million to DKK 114 million and a corresponding increase in goodwill from DKK 222 million to DKK 294 million compared with the amounts disclosed in the half-year interim report. The final purchase price allocation may be adjusted during the measurement period in accordance with IFRS 3, but no later than 12 months from the acquisition date. Announcement no. 07/2026 | 18 August 2026 28
Page 29
Intangible assets consist of customer relationships (DKK 33 million) and technology (DKK 147 million). Customer relationships consist of access to Uromedica’s existing customer base and established relationships with healthcare professionals involved in the treatment of stress urinary incontinence. Technology is associated with Uromedica’s proprietary medical technology and products within interventional urology. Trade receivables represent a gross amount of DKK 10 million and have only been subject to insignificant writedowns. After recognition of identifiable assets and liabilities at fair value, goodwill related to the acquisition amounts to DKK 294 million, which is not deductible for tax purposes. Goodwill expresses expected future earnings and includes synergies expected to be achieved from Coloplast’s strengthened position within men’s health and its enhanced product and technology offering in Interventional Urology. Details of the purchase consideration, the assets and liabilities recognised as a result of the acquisition are as follows: DKK million Fair value Assets identified at fair value: Intangibles assets 180 Property, plant and equipment 1 Inventories 4 Trade receivables and other receivables 11 Cash and cash equivalents 8 Total assets 204 Liability identified at fair value: Provision 4 Trade payables 2 Other payables 32 Deferred tax liability 114 Total liability 152 Total net assets acquired 52 Goodwill 294 Consideration transferred 346 Contingent consideration -210 Acquired cash and current debt to credit institutions 3 Cash consideration paid 139 Earnings impact Uromedica excluding PPA amortisation, is recognised in the consolidated income statement at a revenue of DKK 26 million and in consolidated operating profit before special items at DKK 11 million for the reporting period. The pro forma effect on consolidated revenue and operating profit before special items for the reporting period, as if the company had been acquired on 1 October 2025, amounted to approximately DKK 49 million and DKK 17 million.. Fair value measurement Material net assets acquired for which significant estimates and judgements have been applied in the fair value assessment have been recognised using the following valuation techniques: Customer relationships Customer relationships have been valued using the income-Multi-period Excess Method (MEEM), by which the present value of future cash flows from recurring contract customers expected to be retained after the date of acquisition has been valuated using a WACC of 15.0% as discount rate. The main input drivers in the MEEM model used are the estimated future retention rate and net cash flow of the acquired contract customer base. Announcement no. 07/2026 | 18 August 2026 29
Page 30
Technology Technology has been measured by using the income-Multi-period Excess Method (MEEM), by which the present value of future cash flows from a specific asset is isolated. The discount rate applied is 18.3% which is deemed a fair reflection of the risk comprised in the technology. Note 10 Impairment During the first nine months of 2025/26, Coloplast has recognised a non-cash impairment loss of DKK 3.0 billion of goodwill related to the Biologics operating segment. The goodwill subject to impairment was arising from the acquisition of Kerecis. As a result of significant sales disruption from the Medicare reimbursement change in the outpatient setting and a slower market recovery than previously anticipated within the Biologics operating segment, Coloplast performed an updated impairment test for the segment as at 31 March 2026. Kerecis is now expected to deliver revenue growth of around 0% for FY 2025/26, compared with approximately 25% applied in the impairment test in the Annual Report 2024/25. In addition, the compound annual growth rate for the forecast period 2026/27 to 2034/35 has been reduced from approximately 12% (ranging from 2%-29% during the period) to approximately 10% (10% annually for the period 2026/27 to 2034/35). The terminal growth rate has been increased from 2.0% to 2.5%, reflecting updated long-term market assumptions as a result of the reduced expectations within the budget period and corresponds to the expected long-term rate of inflation. The discount rate before tax of 11.6% (discount rate after tax of 9.0%) is unchanged. Expected EBIT-margins have been lowered as overhead cost projections have been updated. The forecast period exceeds five years as the cash-generating unit is in a growth phase and management considers a longer forecast horizon necessary to reflect the expected pattern of future cash flows. The forecast covers the period 2026-2035 while the impairment test performed at 30.09.2025 covered the period 2026-2040. Following the transfer of IP rights from Iceland to Denmark, the tax rate applied in the impairment test has been increased to 23.0%, compared with 21.6% applied in the previous impairment test. Working capital invested has been projected using the same growth rate as that for revenue. Based on the updated impairment test, management has concluded that the recoverable amount for the Biologics operating segment, determined using a value-in-use approach, was below its carrying amount, consequently a non-cash impairment loss of DKK 3.0 billion was recognised against goodwill in the six-month period ending 31 March 2026. Following the impairment, the total carrying book value of Kerecis amounts to approximately DKK 6.0 billion, compared with approximately DKK 9.0 billion previously and carrying value of goodwill assigned to the Biologics operating segment amounts to approximately DKK 2.5 billion, compared with approximately DKK 5.5 billion previously. No new impairment indicators have been identified since the updated impairment test. Announcement no. 07/2026 | 18 August 2026 30
Page 31
Income statement, quarterly Unaudited Consolidated 2025/26 2024/25 DKK million Q3 Q2 Q1 Q4 Q3 Q2 Q1 Revenue 7,355 7,084 7,043 6,960 6,958 6,930 7,026 Production costs -2,447 -2,367 -2,308 -2,198 -2,253 -2,202 -2,276 Gross profit 4,908 4,717 4,735 4,762 4,705 4,728 4,750 Distribution costs -2,400 -2,349 -2,320 -2,252 -2,243 -2,326 -2,329 Administrative expenses -323 -317 -324 -340 -335 -300 -295 Research and development costs -281 -254 -247 -249 -239 -239 -219 Other operating income 39 30 11 70 38 38 13 Other operating expenses -14 -7 -5 -39 -11 -10 -8 Operating profit (EBIT) before special items 1,929 1,820 1,850 1,952 1,915 1,891 1,912 Special items -18 -3,025 -35 -228 -83 -84 -74 Operating profit (EBIT) 1,911 -1,205 1,815 1,724 1,832 1,807 1,838 Financial income 169 149 166 23 -75 -41 200 Financial expenses -206 -188 -190 -192 -415 -275 -269 Profit before tax 1,874 -1,244 1,791 1,555 1,342 1,491 1,769 Tax on profit for the period -412 273 -394 -680 -537 -579 -725 Net profit for the period 1,462 -971 1,397 875 805 912 1,044 DKK Earnings per share (EPS) before special items 6.55 6.16 6.32 4.67 3.86 4.34 4.89 Earnings per share (EPS) 6.49 -4.31 6.20 3.88 3.57 4.05 4.63 Earnings per share (EPS) before special items, diluted 6.55 6.16 6.32 4.67 3.86 4.34 4.89 Earnings per share (EPS), diluted 6.49 -4.31 6.20 3.88 3.57 4.05 4.63 Announcement no. 07/2026 | 18 August 2026 31
Page 32
Our mission Making life easier for people with intimate health care needs Our values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Our vision Setting the global standard for listening and responding For further information, please contact Investors and analysts Press and media Address Anders Lonning-Skovgaard Peter Mønster Coloplast A/S Executive Vice President, CFO Head of Media Relations & Corporate Content Holtedam 1 +45 4911 1111 +45 4911 2623 DK -3050 Humlebaek dkpete@coloplast.com Denmark Kristine Husted Munk Company reg. (CVR) no. 69 74 99 17 Senior Director, Investor Relations +45 4911 1800 / +45 4911 3266 Website dkkhu@coloplast.com www.coloplast.com Simone Dyrby Helvind Senior Manager, Investor Relations +45 4911 1800 / +45 4911 2981 dksdk@coloplast.com This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. The Coloplast story begins back in 1954. Elise Sørensen is a nurse. Her sister Thora has just had an ostomy operation and is afraid to go out in public, fearing that her stoma might leak. Listening to her sister’s problems, Elise conceives the idea of the world’s first adhesive ostomy bag. Based on Elise’s idea, Aage Louis-Hansen, a civil engineer and plastics manufacturer, and his wife Johanne Louis- Hansen, a trained nurse, created the ostomy bag. A bag that does not leak, giving Thora – and thousands of people like her – the chance to live the life they want. A simple solution that makes a difference. Today, the Coloplast Group develops products and services that help millions of people live more independent lives through solutions tailored to their needs. Globally, our business areas include Ostomy Care, Continence Care, Voice & Respiratory Care, Wound & Tissue Repair, and Interventional Urology. The Coloplast logo is a registered trademark of Coloplast A/S© 2026-08 All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark Announcement no. 07/2026 | 18 August 2026 32